Notice of allowance of Breast Cancer Patent in Japan

DiaGenic has received notice of allowance of the family 3 patent application in Japan ( 2007-514130). The claims allowed cover the use of some important gene sequences in blood sample for detection and monitoring of breast cancer. The patent will be valid until 2025. Family 3 patents have earlier been granted in US and Europe.

"The new Japanese patent is an important milestone which strengthens our position in Asia. The company will now have a broad patent protection in Japan, one of the largest economies in the world” said DiaGenic CEO Henrik Lund MD PhD.

Contact:

Henrik Lund, CEO

Telephone: 47 90971219

e-mail: henrik.lund@diagenic.com

About DiaGenic ASA

DiaGenic seeks to create value for patients, partners, and investors by developing innovative and more patient friendly methods for early detection of diseases utilizing DiaGenic’s unique concept. The concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using blood samples.

DiaGenic is a world leader in identifying these gene expression signatures in peripheral blood and is focused on the development of biomarkers in the field of Alzheimer’s disease and Parkinson’s disease. DiaGenic’s Alzheimer’s disease development program includes the CE marked diagnostic test ADtect®, for detection of mild to moderate Alzheimer’s disease, and MCItect®which is under development for identifying patients with very early stages of Alzheimer’s disease (prodromal AD).

DiaGenic’s concept is protected through an extensive patent portfolio. DiaGenic promotes its products and services towards leading pharmaceutical, imaging and diagnostic companies. DiaGenic is located in Norway and listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com